Novel antimicrobial agents for combating antibiotic-resistant bacteria.
Adv Drug Deliv Rev
; 187: 114378, 2022 08.
Article
em En
| MEDLINE
| ID: mdl-35671882
ABSTRACT
Antibiotic therapy has become increasingly ineffective against bacterial infections due to the rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) have caused life-threatening infections in humans and represent a major global health threat due to a high degree of antibiotic resistance. To respond to this urgent call, novel strategies are urgently needed, such as bacteriophages (or phages), phage-encoded enzymes, immunomodulators and monoclonal antibodies. This review critically analyses these promising antimicrobial therapies for the treatment of multidrug-resistant bacterial infections. Recent advances in these novel therapeutic strategies are discussed, focusing on preclinical and clinical investigations, as well as combinatorial approaches. In this 'Bad Bugs, No Drugs' era, novel therapeutic strategies can play a key role in treating deadly infections and help extend the lifetime of antibiotics.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Infecções Bacterianas
/
Bacteriófagos
/
Enterococcus faecium
/
Acinetobacter baumannii
Limite:
Humans
Idioma:
En
Revista:
Adv Drug Deliv Rev
Ano de publicação:
2022
Tipo de documento:
Article